Research landscape and trends of lung cancer radiotherapy: A bibliometric analysis

被引：9

作者：

Liu, Yanhao ^{[1
]}

Jiang, Shu ^{[1
]}

Lin, Yaru ^{[1
]}

Yu, Haiming ^{[1
]}

Yu, Lan ^{[1
]}

Zhang, Xiaotao ^{[1
]}

机构：

[1] Qingdao Univ, Affiliated Qingdao Cent Hosp, Dept Radiat Oncol, Qingdao, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

bibliometric analysis; lung cancer; radiotherapy; chemotherapy; chemoradiotherapy; SBRT; SAbR; immunotherapy; STEREOTACTIC ABLATIVE RADIOTHERAPY; PROPHYLACTIC CRANIAL IRRADIATION; BODY RADIATION-THERAPY; PHASE-III TRIAL; HYPOFRACTIONATED PROTON THERAPY; DAILY THORACIC RADIOTHERAPY; LOCATED EARLY-STAGE; OPEN-LABEL; RANDOMIZED-TRIAL; POSTOPERATIVE RADIOTHERAPY;

D O I：

10.3389/fonc.2022.1066557

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Backgroundradiotherapy is one of the major treatments for lung cancer and has been a hot research area for years. This bibliometric analysis aims to present the research trends on lung cancer radiotherapy. MethodOn August 31, 2022, the authors identified 9868 articles on lung cancer radiotherapy by the Web of Science (Science Citation Indexing Expanded database) and extracted their general information and the total number of citations. A bibliometric analysis was carried out to present the research landscape, demonstrate the research trends, and determine the most cited papers (top-papers) as well as top-journals on lung cancer radiotherapy. After that, the authors analyzed the recent research hotspots based on the latest publications in top-journals. ResultsThese 9868 papers were cited a total of 268,068 times. "Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer" published in 2017 by Antonia et al.was the most cited article (2110 citations). Among the journals, New England Journal of Medicine was most influential. Moreover, J. Clin. Oncol. and Int. J. Radiat. Oncol. Biol. Phys. was both influential and productive. Corresponding authors represented the USA (2610 articles) and China mainland (2060 articles) took part in most publications and articles with corresponding authors from Netherlands were most cited (46.12 citations per paper). Chemoradiotherapy was the hottest research area, and stereotactic body radiotherapy has become a research hotspot since 2006. Radiotherapy plus immunotherapy has been highly focused since 2019. ConclusionsThis bibliometric analysis comprehensively and quantitatively presents the research trends and hotspots based on 9868 relevant articles, and further suggests future research directions. The researchers can benefit in selecting journals and in finding potential collaborators. This study can help researchers gain a comprehensive picture of the research landscape, historical development, and recent hotspots in lung cancer radiotherapy and can provide inspiration for future research.

引用

页数：21

共 101 条

[1] CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].

ALBAIN, KS ;

RUSCH, VW ;

CROWLEY, JJ ;

RICE, TW ;

TURRISI, AT ;

WEICK, JK ;

LONCHYNA, VA ;

PRESANT, CA ;

MCKENNA, RJ ;

GANDARA, DR ;

FOSMIRE, H ;

TAYLOR, SA ;

STELZER, KJ ;

BEASLEY, KR ;

LIVINGSTON, RB .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892

[2] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial [J].

Altorki, Nasser K. ;

McGraw, Timothy E. ;

Borczuk, Alain C. ;

Saxena, Ashish ;

Port, Jeffrey L. ;

Stiles, Brendon M. ;

Lee, Benjamin E. ;

Sanfilippo, Nicholas J. ;

Scheff, Ronald J. ;

Pua, Bradley B. ;

Gruden, James F. ;

Christos, Paul J. ;

Spinelli, Cathy ;

Gakuria, Joyce ;

Uppal, Manik ;

Binder, Bhavneet ;

Elemento, Olivier ;

Ballman, Karla, V ;

Formenti, Silvia C. .

LANCET ONCOLOGY, 2021, 22 (06) :824-835

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] PROPHYLACTIC CRANIAL IRRADIATION FOR PATIENTS WITH SMALL-CELL LUNG-CANCER IN COMPLETE REMISSION [J].

ARRIAGADA, R ;

LECHEVALIER, T ;

BORIE, F ;

RIVIERE, A ;

CHOMY, P ;

MONNET, I ;

TARDIVON, A ;

VIADER, F ;

TARAYRE, M ;

BENHAMOU, S .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (03) :183-190

[5] Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial) [J].

Arrieta, Oscar ;

Maldonado, Federico ;

Turcott, Jenny G. ;

Lucia Zatarain-Barron, Zyanya ;

Barron, Feliciano ;

Blake-Cerda, Monika ;

Antonio Cabrera-Miranda, Luis ;

Cardona, Andres F. ;

de la Garza, Jaime G. ;

Rosell, Rafael .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (05) :1442-1450

[6] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].

Aupérin, A ;

Arriagada, R ;

Pignon, JP ;

Le Péchoux, C ;

Gregor, A ;

Stephens, RJ ;

Kristjansen, PEG ;

Johnson, BE ;

Ueoka, H ;

Wagner, H ;

Aisner, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484

[7] Clinical Outcomes Following Proton and Photon Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer [J].

Bae, Bong Kyung ;

Yang, Kyungmi ;

Noh, Jae Myung ;

Pyo, Hongryull ;

Ahn, Yong Chan .

CANCERS, 2022, 14 (17)

[8] Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC) [J].

Bahig, Houda ;

Tonneau, Marion ;

Blais, Normand ;

Wong, Philip ;

Filion, Edith ;

Campeau, Marie-Pierre ;

Vu, Toni ;

Al-Saleh, Afnan ;

Tehfe, Mustapha ;

Florescu, Marie ;

Roberge, David ;

Masucci, Laura ;

Richard, Corentin ;

Menard, Cynthia ;

Routy, Bertrand .

CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 33 :115-119

[9] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial [J].

Ball, David ;

Mai, G. Tao ;

Vinod, Shalini ;

Babington, Scott ;

Ruben, Jeremy ;

Kron, Tomas ;

Chesson, Brent ;

Herschtal, Alan ;

Vanevski, Marijana ;

Rezo, Angela ;

Elder, Christine ;

Skala, Marketa ;

Wirth, Andrew ;

Wheeler, Greg ;

Lim, Adeline ;

Shaw, Mark ;

Schofield, Penelope ;

Irving, Louis ;

Solomon, Benjamin .

LANCET ONCOLOGY, 2019, 20 (04) :494-503

[10] Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction [J].

Belluomini, Lorenzo ;

Dionisi, Valeria ;

Palmerio, Silvia ;

Vincenzi, Sofia ;

Avancini, Alice ;

Casali, Miriam ;

Riva, Silvia Teresa ;

Menis, Jessica ;

Mazzarotto, Renzo ;

Pilotto, Sara ;

Milella, Michele .

CLINICAL LUNG CANCER, 2022, 23 (03) :E269-E272

← 1 2 3 4 5 6 7 8 9 10 →